Baseline characteristics of type 2 diabetes patients who initiated GLP-1 receptor agonists (GLP-1RAs) or other non-GLP-1RA anti-diabetic drugs (Control) between January 2011 and March 2014 in primary care in Germany.

Real world evidence on the prescribing trends of glucagon-like peptide-1 agonists in UK primary care

Hinton, W
McGovern, A
van Vlymen, J
Munro, N
Whyte, MB
de Lusignan, S

March 2016

Aim The use of glucagon-like peptide-1 (GLP-1) agonists in type 2 diabetes is increasing. We present...

Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists

Fujihara, Kazuya
Hanyu, Osamu
Heianza, Yoriko
Suzuki, Akiko
Yamada, Takaho
Yokoyama, Hiroki
Tanaka, Shiro
Yagyu, Hiroaki
Shimano, Hitoshi
Kashiwagi, Atsunori
Yamazaki, Katuya
Kawai, Koichi
Sone, Hirohito

March 2016

Aims/Introduction: We compared clinical characteristics in patients with type 2 diabetes for whom di...

Baseline characteristics of studies comparing glyburide and insulin in the treatment of GDM.

Rongjing Song (133760)
Ling Chen (25698)
Yue Chen (73753)
Xia Si (4329826)
Yi Liu (36759)
Yue Liu (292931)
David M. Irwin (49704)
Wanyu Feng (4220677)

August 2017

Baseline characteristics of studies comparing glyburide and insulin in the treatment of GDM.</p

Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany.

Qing Qiao
Susan Grandy
Josh Hiller
Karel Kostev

AIMS:To investigate real-world clinical and patient-related variables associated with initiating GLP...

Clinical and patient-related variables associated with initiating GLP-1 receptor agonist therapy in type 2 diabetes patients in primary care in Germany

Qiao, Qing
Grandy, Susan
Hiller, Josh
Kostev, Karel

March 2016

Aims: To investigate real-world clinical and patient-related variables associated with initiating GL...

ORIGINAL RESEARCH Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries

Victoria Divino
Mitch Dekoven
Shawn Hallinan
Nebibe Varol
Sara Bruce
Wirta Won
Chan Lee
Matthew Reaney

January 2014

The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: The...

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain

Conget, Ignacio
Mauricio, Dídac
Ortega, Rafael
Detournay, Bruno
Muros, Teresa
De la Cuesta, Carmen
Mangas Cruz, Miguel Ángel
Hernández Herrero, Cristina
De Castro Hernández, Paloma
Gómez Peralta, Fernando
Miralles García, José Manuel
Martínez, Encarna
Cuatrecasas, Guillem
Aguilera, Eva
Giménez, Margarita
Vinagre, Irene
Anglada, Jordi
Pérez Maraver, Manuel
Manzanares, Jose María
Fernández Catalina, Pablo
Bellido Guerrero, Diego
Soto González, Alfonso
Casanueva, Felipe
Masmiquel, Lluís
Gómez, Luis Alberto
García, Honorato
Arguelles, Iñaqui
Garcia Puig, Juan
Brito Sanfiel, Miguel Ángel
Escalada, Francisco Javier
Gaztambide, Sonia
Hernández Mijares, Antonio
Ampudia Blasco, Francisco Javier
Tréscoli, Carlos
Merino Torres, Juan Francisco
De Teresa Parreño, Luis

January 2016

Objective: Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recent...

Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes : Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia

Franch-Nadal, Josep
Mata-Cases, Manel
Ortega, Emilio
Real, Jordi
Gratacòs, Mònica
Vlacho, Bogdan
Vallés, Joan Antoni
Mauricio Puente, Dídac
Universitat Autònoma de Barcelona

January 2019

To assess the clinical characteristics, the prescription pattern of GLP-1 receptor agonists (GLP-1RA...

Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline

Deeg Evelin
Plate Tanja
Krekler Michael
Gitt Anselm K
Binz Christiane
Bramlage Peter
Tschöpe Diethelm

September 2010

Abstract Background Patients with type 2 diabetes are at an increased risk for disease and treatment...

Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis

Kostev K
Dippel FW
Rathmann W

January 2015

Karel Kostev,1 Franz W Dippel,2 Wolfgang Rathmann3 1IMS Health, Frankfurt, 2Sanofi-Aventis Deutschla...

Baseline characteristics of type 1 diabetic patients enrolled in the study.

Sung Shin (3401819)
Chang Hee Jung (107447)
Ji Yoon Choi (4567984)
Hyun Wook Kwon (4804029)
Joo Hee Jung (4567987)
Young Hoon Kim (554681)
Duck Jong Han (3998090)

January 2018

Baseline characteristics of type 1 diabetic patients enrolled in the study.</p

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study

Longato E.
Di Camillo B.
Sparacino G.
Tramontan L.
Avogaro A.
Fadini G. P.

January 2021

Aim: We aimed to compare cardiovascular outcomes of patients with type 2 diabetes (T2D) who initiate...

Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study

Thorsten Otto (5865491)
Melissa Myland (4688413)
Heike Jung (5865494)
Jeremie Lebrec (4887775)
Hartmut Richter (3046278)
Kirsi Norrbacka (4887766)

April 2019

Objective: This retrospective database analysis complements previous research to understand treatmen...

Socio-demographic and baseline characteristics of patients with diabetic (N = 387).

Adeladlew Kassie Netere (4621486)
Ashenafi Kibret Sendekie (12646960)

September 2022

Socio-demographic and baseline characteristics of patients with diabetic (N = 387).</p

Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists

Sciannameo, Veronica
Berchialla, Paola
Orsi, Emanuela
Lamacchia, Olga
Morano, Susanna
Querci, Fabrizio
Consoli, Agostino
Avogaro, Angelo
Fadini, Gian Paolo

January 2020

Aim To evaluate the generalizability of cardiovascular outcome trials (CVOTs) on glucagon-like pepti...

Real world evidence on the prescribing trends of glucagon-like peptide-1 agonists in UK primary care

Hinton, W
McGovern, A
van Vlymen, J
Munro, N
Whyte, MB
de Lusignan, S

March 2016

Aim The use of glucagon-like peptide-1 (GLP-1) agonists in type 2 diabetes is increasing. We present...

Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists

Fujihara, Kazuya
Hanyu, Osamu
Heianza, Yoriko
Suzuki, Akiko
Yamada, Takaho
Yokoyama, Hiroki
Tanaka, Shiro
Yagyu, Hiroaki
Shimano, Hitoshi
Kashiwagi, Atsunori
Yamazaki, Katuya
Kawai, Koichi
Sone, Hirohito

March 2016

Aims/Introduction: We compared clinical characteristics in patients with type 2 diabetes for whom di...

Baseline characteristics of studies comparing glyburide and insulin in the treatment of GDM.

Rongjing Song (133760)
Ling Chen (25698)
Yue Chen (73753)
Xia Si (4329826)
Yi Liu (36759)
Yue Liu (292931)
David M. Irwin (49704)
Wanyu Feng (4220677)

August 2017

Baseline characteristics of studies comparing glyburide and insulin in the treatment of GDM.</p

Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany.

Qing Qiao
Susan Grandy
Josh Hiller
Karel Kostev

AIMS:To investigate real-world clinical and patient-related variables associated with initiating GLP...

Clinical and patient-related variables associated with initiating GLP-1 receptor agonist therapy in type 2 diabetes patients in primary care in Germany

Qiao, Qing
Grandy, Susan
Hiller, Josh
Kostev, Karel

March 2016

Aims: To investigate real-world clinical and patient-related variables associated with initiating GL...

ORIGINAL RESEARCH Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries

Victoria Divino
Mitch Dekoven
Shawn Hallinan
Nebibe Varol
Sara Bruce
Wirta Won
Chan Lee
Matthew Reaney

January 2014

The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: The...

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain

Conget, Ignacio
Mauricio, Dídac
Ortega, Rafael
Detournay, Bruno
Muros, Teresa
De la Cuesta, Carmen
Mangas Cruz, Miguel Ángel
Hernández Herrero, Cristina
De Castro Hernández, Paloma
Gómez Peralta, Fernando
Miralles García, José Manuel
Martínez, Encarna
Cuatrecasas, Guillem
Aguilera, Eva
Giménez, Margarita
Vinagre, Irene
Anglada, Jordi
Pérez Maraver, Manuel
Manzanares, Jose María
Fernández Catalina, Pablo
Bellido Guerrero, Diego
Soto González, Alfonso
Casanueva, Felipe
Masmiquel, Lluís
Gómez, Luis Alberto
García, Honorato
Arguelles, Iñaqui
Garcia Puig, Juan
Brito Sanfiel, Miguel Ángel
Escalada, Francisco Javier
Gaztambide, Sonia
Hernández Mijares, Antonio
Ampudia Blasco, Francisco Javier
Tréscoli, Carlos
Merino Torres, Juan Francisco
De Teresa Parreño, Luis

January 2016

Objective: Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recent...

Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes : Prescription According to Reimbursement Constraints and Guideline Recommendations in Catalonia

Franch-Nadal, Josep
Mata-Cases, Manel
Ortega, Emilio
Real, Jordi
Gratacòs, Mònica
Vlacho, Bogdan
Vallés, Joan Antoni
Mauricio Puente, Dídac
Universitat Autònoma de Barcelona

January 2019

To assess the clinical characteristics, the prescription pattern of GLP-1 receptor agonists (GLP-1RA...

Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline

Deeg Evelin
Plate Tanja
Krekler Michael
Gitt Anselm K
Binz Christiane
Bramlage Peter
Tschöpe Diethelm

September 2010

Abstract Background Patients with type 2 diabetes are at an increased risk for disease and treatment...

Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis

Kostev K
Dippel FW
Rathmann W

January 2015

Karel Kostev,1 Franz W Dippel,2 Wolfgang Rathmann3 1IMS Health, Frankfurt, 2Sanofi-Aventis Deutschla...

Baseline characteristics of type 1 diabetic patients enrolled in the study.

Sung Shin (3401819)
Chang Hee Jung (107447)
Ji Yoon Choi (4567984)
Hyun Wook Kwon (4804029)
Joo Hee Jung (4567987)
Young Hoon Kim (554681)
Duck Jong Han (3998090)

January 2018

Baseline characteristics of type 1 diabetic patients enrolled in the study.</p

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study

Longato E.
Di Camillo B.
Sparacino G.
Tramontan L.
Avogaro A.
Fadini G. P.

January 2021

Aim: We aimed to compare cardiovascular outcomes of patients with type 2 diabetes (T2D) who initiate...

Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study

Thorsten Otto (5865491)
Melissa Myland (4688413)
Heike Jung (5865494)
Jeremie Lebrec (4887775)
Hartmut Richter (3046278)
Kirsi Norrbacka (4887766)

April 2019

Objective: This retrospective database analysis complements previous research to understand treatmen...

Socio-demographic and baseline characteristics of patients with diabetic (N = 387).

Adeladlew Kassie Netere (4621486)
Ashenafi Kibret Sendekie (12646960)

September 2022

Socio-demographic and baseline characteristics of patients with diabetic (N = 387).</p

Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists

Sciannameo, Veronica
Berchialla, Paola
Orsi, Emanuela
Lamacchia, Olga
Morano, Susanna
Querci, Fabrizio
Consoli, Agostino
Avogaro, Angelo
Fadini, Gian Paolo

January 2020

Aim To evaluate the generalizability of cardiovascular outcome trials (CVOTs) on glucagon-like pepti...

Real world evidence on the prescribing trends of glucagon-like peptide-1 agonists in UK primary care

Hinton, W
McGovern, A
van Vlymen, J
Munro, N
Whyte, MB
de Lusignan, S

March 2016

Aim The use of glucagon-like peptide-1 (GLP-1) agonists in type 2 diabetes is increasing. We present...

Comparison of clinical characteristics in patients with type 2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists

Fujihara, Kazuya
Hanyu, Osamu
Heianza, Yoriko
Suzuki, Akiko
Yamada, Takaho
Yokoyama, Hiroki
Tanaka, Shiro
Yagyu, Hiroaki
Shimano, Hitoshi
Kashiwagi, Atsunori
Yamazaki, Katuya
Kawai, Koichi
Sone, Hirohito

March 2016

Aims/Introduction: We compared clinical characteristics in patients with type 2 diabetes for whom di...

Baseline characteristics of studies comparing glyburide and insulin in the treatment of GDM.

Rongjing Song (133760)
Ling Chen (25698)
Yue Chen (73753)
Xia Si (4329826)
Yi Liu (36759)
Yue Liu (292931)
David M. Irwin (49704)
Wanyu Feng (4220677)

August 2017

Baseline characteristics of studies comparing glyburide and insulin in the treatment of GDM.</p

Baseline characteristics of type 2 diabetes patients who initiated GLP-1 receptor agonists (GLP-1RAs) or other non-GLP-1RA anti-diabetic drugs (Control) between January 2011 and March 2014 in primary care in Germany.

Abstract

Extracted data

Baseline characteristics of type 2 diabetes patients who initiated GLP-1 receptor agonists (GLP-1RAs) or other non-GLP-1RA anti-diabetic drugs (Control) between January 2011 and March 2014 in primary care in Germany.

Abstract

Extracted data

Related items

Related items